Azitra (AZTR) Common Equity (2022 - 2026)
Azitra (AZTR) reported Common Equity of $10.5 million for Q1 2026, up 137.7% on a YoY basis from $4.4 million in Q1 2025, and up 175.71% quarter-over-quarter from $3.8 million in Q4 2025.
Azitra (AZTR) Common Equity (2022 - 2026) Analysis & Trends
Azitra has reported Common Equity for 5 years, with the latest figure at $10.5 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 137.7% year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2026 stood at $10.5 million (up 137.7% YoY), and the FY2025 full-year result was $3.8 million, down 33.29% from the prior year.
- Common Equity for Q1 2026 stood at $10.5 million, up from $3.8 million in the prior quarter.
- The five-year high for Common Equity was $10.5 million in Q1 2026, with the low at -$38.7 million in Q1 2023.
- Historically, Common Equity has averaged -$4.9 million across 5 years, with a median of $3.4 million in 2023.
- Annual changes were most pronounced in 2024 — Common Equity plunged 76.15% — and 2026, when it soared 137.7%.
- Azitra's Common Equity stood at -$36.3 million in 2022, then surged by 108.03% to $2.9 million in 2023, then jumped by 95.61% to $5.7 million in 2024, then plunged by 33.29% to $3.8 million in 2025, then jumped by 175.71% to $10.5 million in 2026.
- The last three Common Equity figures came in at $10.5 million (Q1 2026), $3.8 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 10.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.48 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 4.41 Mn |
| Dec 31, 2024 | 5.70 Mn |
| Sep 30, 2024 | 8.06 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 2.91 Mn |
| Sep 30, 2023 | 5.33 Mn |
| Jun 30, 2023 | 7.24 Mn |
| Mar 31, 2023 | -38.68 Mn |
| Dec 31, 2022 | -36.26 Mn |
| Sep 30, 2022 | -32.24 Mn |
| Jun 30, 2022 | -29.87 Mn |